A new study shows more Americans are saving for college again. » Read More
Here's why Evan McMullin's third-party presidential run won't tip a single swing state into the Clinton column, says Jake Novak.
Projected deficits of America's most popular retirement program vary by trillions of dollars. Find out why.
VW shares are rising from the depths, should you buy now?
Oil rose on Monday on a report of renewed calls by some OPEC members to restrain output, but analysts warned bearish fundamentals remain.
RBC Capital's Helima Croft explains why she expects oil to go higher despite a number of misdirection plays.
"Suicide Squad" is likely to blow away the competition based on branding and beloved star castings, according to a senior movie analyst.
Gold's tumble in the wake of strong U.S. data has chastened at least a few bulls, even while others are unapologetically optimistic.
Biotech stocks this week hit their highest levels since January. And some analysts say the stocks have room to run.
Even with the S&P 500 hitting a new all-time intraday high, stocks still look attractive, said Wunderlich Securities' Art Hogan.
A look at luxury home markets seeing a boost, with Hessam Nadji, Marcus & Millichap.
The latest reading on luxury home prices shows a small increase compared to last year. CNBC's Diana Olick reports.
CNBC's Kate Rogers reports on where today's jobs are, from Salt Lake City, Utah.
Fred Yang, Hart Research, discusses the Wall Street Journal/NBC poll that showed Hillary Clinton has opened a 9-point lead on Republican challenger Donald Trump.
CNBC's John Harwood reports that the Donald Trump campaign plans to release its economic plan on Monday.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
Where stocks can go from here, with Art Hogan, Wunderlich, and Kate Warne, Edward Jones.